期刊文献+

基于AMPK/mTOR通路的天然产物抗大肠癌研究进展 被引量:1

Research Progress in anti-Colorectal Cancer of Natural Compounds Based on AMPK/mTOR Signalling Pathway
原文传递
导出
摘要 大肠癌是严重危害人类健康的常见恶性消化系统肿瘤之一,目前临床上大肠癌的主要治疗手段是手术结合放化疗,但往往伴随着多种副作用。与此同时,越来越多的天然产物表现出良好的抗大肠癌活性,有望成为新型大肠癌治疗候选药物。AMP依赖的蛋白激酶(AMPK)是细胞内能量代谢的中心枢纽,可以通过抑制其下游靶标哺乳动物雷帕霉素靶蛋白(mTOR)而调控肿瘤细胞生长、增殖等。近年来,越来越多的研究显示一些天然产物能够通过调控AMPK/m TOR通路而发挥其抗大肠癌活性。围绕AMPK/mTOR信号通路在大肠癌中的作用及基于此通路的抗大肠癌天然产物的研究进展进行综述。 Colorectal cancer,one of the most common malignant tumors of the digestive system,is a major public health threat worldwide.At present,the main treatment for colorectal cancer is surgery combined with radiotherapy and chemotherapy,but it is often accompanied by various side effects.At the same time,some natural compounds with good anti-colorectal cancer activity are expected to become new drug candidates for colorectal cancer treatment.AMP-dependent protein kinase(AMPK),a central hub of intracellular energy metabolism,can regulate tumor cell growth and proliferation by inhibiting its downstream target mammalian rapamycin target protein(mTOR).In recent years,more and more studies have shown that some natural products exert their anti-colorectal cancer activity by regulating the AMPK/mTOR pathway.This article focuses on the role of AMPK/mTOR signalling pathway in colorectal cancer with a review of the research progress of anti-colorectal cancer natural products regulating AMPK/mTOR signalling pathway.
作者 魏青 闻晓东 WEI Qing;WEN Xiaodong(State Key Laboratory of Natural Medicines,China Pharmaceutical University,Nanjing 210009,China)
出处 《药学进展》 CAS 2019年第10期793-800,共8页 Progress in Pharmaceutical Sciences
基金 国家自然科学基金面上项目(No.81573567).
关键词 大肠癌 天然产物 AMP依赖的蛋白激酶 雷帕霉素靶蛋白 colorectal cancer natural compound AMPK mTOR
  • 相关文献

参考文献2

二级参考文献11

  • 1Alberto Morán,Paloma Ortega,Carmen de Juan,Tamara Fernández-Marcelo,Cristina Frías,Andrés Sánchez-Pernaute,Antonio José Torres,Eduardo Díaz-Rubio,Pilar Iniesta,Manuel Benito.Differential colorectal carcinogenesis:Molecular basis and clinical relevance[J].World Journal of Gastrointestinal Oncology,2010,2(3):151-158. 被引量:5
  • 2Céline Chu,Marie‐Sophie No?l‐Hudson,Valérie Boige,Diane Goéré,Sylvie Marion,Mélanie Polrot,Ludovic Bigot,Patrick Gonin,Robert Farinotti,Laurence Bonhomme‐Faivre.Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation[J].Fundamental & Clinical Pharmacology.2013(4)
  • 3Kimmie Ng,Josep Tabernero,Jimmy Hwang,Emilio Bajetta,Sunil Sharma,Salvatore A. Del Prete,Edward R. Arrowsmith,David P. Ryan,Michaela Sedova,Jin Jin,Kamel Malek,Charles S. Fuchs.Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens[J].Clinical Cancer Research.2013(14)
  • 4Ivy Altomare,Herbert Hurwitz.Everolimus in colorectal cancer[J].Expert Opinion on Pharmacotherapy.2013(4)
  • 5Erika Martinelli,Teresa Troiani,Elena D’Aiuto,Floriana Morgillo,Donata Vitagliano,Anna Capasso,Sarah Costantino,Loreta Pia Ciuffreda,Francesco Merolla,Loredana Vecchione,Veerle Vriendt,Sabine Tejpar,Anna Nappi,Vincenzo Sforza,Giulia Martini,Liberato Berrino,Raffaele Palma,Fortunato Ciardiello.Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cells[J].Int J Cancer.2013(9)
  • 6Areumnuri Kim,Jung‐Eun Lee,Seung‐Sook Lee,Cherin Kim,Sun‐Joo Lee,Won‐Suk Jang,Sunhoo Park.Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP‐BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer[J].Int J Cancer.2013(4)
  • 7Karen-Lise G. Spindler,Morten M. Sorensen,Niels Pallisgaard,Rikke F. Andersen,Birgitte M. Havelund,John Ploen,Ulrik Lassen,Anders K. M. Jakobsen.Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma[J].Acta Oncologica.2013(5)
  • 8Shi-Yong Sun.mTOR kinase inhibitors as potential cancer therapeutic drugs[J].Cancer Letters.2013
  • 9Brian Shuch,Christopher J. Ricketts,Cathy D. Vocke,Takefumi Komiya,Lindsay A. Middelton,Eric C. Kauffman,Maria J. Merino,Adam R. Metwalli,Phillip Dennis,W. Marston Linehan.Germline PTEN Mutation Cowden Syndrome: An Under-Appreciated Form of Hereditary Kidney Cancer[J].The Journal of Urology.2013
  • 10Shih‐Wei Lai,Kuan‐Fu Liao.Aspirin Use After Diagnosis Improves Survival in Older Adults with Colon Cancer[J].J Am Geriatr Soc.2013(5)

共引文献28

同被引文献18

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部